Hudbay Minerals Inc. Ordinary Shares (Canada) vs Moderna, Inc. — how do they compare? Hudbay Minerals Inc. Ordinary Shares (Canada) trades at $25.79 (market cap $11.52B), while Moderna, Inc. trades at $196.71 (market cap $78.44B). The key difference: Moderna, Inc. is far larger — about 6.8× Hudbay Minerals Inc. Ordinary Shares (Canada)'s market cap, and Hudbay Minerals Inc. Ordinary Shares (Canada) pays a 0.11% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hudbay Minerals Inc. Ordinary Shares (Canada) for 0 Days and Moderna, Inc. for 59 Days on average.
| HBM | MRNA | |
|---|---|---|
Market Cap | $11.52B | $78.44B |
Volume | 4,227,671 | 14,597,511 |
Sector | Basic Materials | Health |
52-Week High | $31.87 | $203.46 |
52-Week Low | $14.58 | $22.36 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $11.58B | $74.59B |
Dividend Yield | 0.11% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.
Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hudbay Minerals is a mining company producing copper, gold, zinc, and other metals. Its operations are located in the Americas.
Read more on HBM →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →